Consensus paper: Pathological mechanisms underlying neurodegeneration in spinocerebellar ataxias

Cerebellum

Volumn 13, Issue 2, 2014, Pages 269-302

  Matilla Duenas A ^a,b   Ashizawa, T ^e   Brice, A ^c,d   Magri, S ^j   McFarland, K N ^e   Pandolfo, M ^f   Pulst, S M ^g   Riess, O ⁱ   Rubinsztein, D C ^h   Schmidt, J ⁱ   Schmidt, T ⁱ   Scoles, D R ^g   Stevanin, G ^c,d   Taroni, F ^j   Underwood, B R ^k   Sanchez I ^b  

^a FUNDACIÓ INSTITUT D INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^e UNIVERSITY OF FLORIDA   (United States)

^f ERASME HOSPITAL   (Belgium)

^g UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^h ADDENBROOKE S HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY OF TÜBINGEN   (Germany)

^j DEPARTMENT OF NEUROSURGERY   (Italy)

^k FULBOURN HOSPITAL   (United Kingdom)

more..

Author keywords

Aggregation; Ataxia; Autophagy; Calcium; Cerebellum; Mitochondria; Neurodegeneration; Neuronal death; Polyglutamine; Purkinje cell; Therapy; Transcription dysregulation

Indexed keywords

3 AMINOPYRIDINE; 3,4 DIAMINOPYRIDINE; ADENOSINE TRIPHOSPHATASE; ALPHA TOCOPHERYLQUINONE; ATAXIN 1; ATAXIN 10; ATAXIN 2; ATAXIN 3; ATAXIN 7; ATAXIN 8; CALCIUM; CALCIUM CHANNEL P TYPE; CALCIUM CHANNEL Q TYPE; CORTICOSTEROID; DEFERIPRONE; ELONGATION FACTOR 2; EPIGALLOCATECHIN GALLATE; FIBROBLAST GROWTH FACTOR 14; HISTONE DEACETYLASE INHIBITOR; IDEBENONE; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR; NUCLEIC ACID BINDING PROTEIN; PRODYNORPHIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; RIBONUCLEOPROTEIN; RNA; SHAL POTASSIUM CHANNEL; SPECTRIN; UNCLASSIFIED DRUG;

APOPTOSIS; ATAXIA; AUTOPHAGY; BIOENERGY; CALCIUM TRANSPORT; CELL DEATH; CHANNEL GATING; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DENTATORUBROPALLIDOLUYSIAN ATROPHY; DISEASE COURSE; DRUG TARGETING; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC TRANSCRIPTION; HUMAN; HUNTINGTON CHOREA; MEDICAL RESEARCH; MITOCHONDRION; MOLECULAR MECHANICS; NERVE CELL; NERVE DEGENERATION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT CARE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPINOCEREBELLAR DEGENERATION;

ANIMALS; AUTOPHAGY; HUMANS; ION CHANNELS; MITOCHONDRIA; NERVE DEGENERATION; RNA; SPINOCEREBELLAR ATAXIAS; TRANSCRIPTION, GENETIC;

EID: 84896261140     PISSN: 14734222     EISSN: 14734230     Source Type: Journal    
DOI: 10.1007/s12311-013-0539-y     Document Type: Conference Paper

References (416)

1. Orr H, Chung M-y, Banfi S, Kwiatkowski Jr TJ, Servadio A, Beaudet AL, et al. Expansion of an unstable trinucleotide (CAG) repeat in spinocerebellar ataxia type 1. Nat Genet. 1993;4:221-6. (Pubitemid 23205168)
2. Jacobi H, Bauer P, Giunti P, Labrum R, Sweeney MG, Charles P, et al. The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study. Neurology. 2011;77:1035-41.
3. Dohlinger S, Hauser TK, Borkert J, Luft AR, Schulz JB. Magnetic resonance imaging in spinocerebellar ataxias. Cerebellum. 2008;7: 204-14.
4. Reetz K, Costa AS, Mirzazade S, Lehmann A, Juzek A, Rakowicz M, et al. Genotype-specific patterns of atrophy progression are more sensitive than clinical decline in SCA1, SCA3 and SCA6. Brain. 2013;136:905-17.
5. Manto MU. The wide spectrum of spinocerebellar ataxias (SCAs). Cerebellum. 2005;4:2-6.
6. Schulz JB, Borkert J, Wolf S, Schmitz-Hubsch T, Rakowicz M, Mariotti C, et al. Visualization, quantification and correlation of brain atrophy with clinical symptoms in spinocerebellar ataxia types 1, 3 and 6. Neuroimage. 2010;49:158-68.
7. Scherzed W, Brunt ER, Heinsen H, de Vos RA, Seidel K, Burk K., et al. Pathoanatomy of cerebellar degeneration in spinocerebellar ataxia type 2 (SCA2) and type 3 (SCA3). Cerebellum. 2012; 11: 749-60.
8. Abraham MC, Lu Y, Shaham S. A morphologically conserved nonapoptotic program promotes linker cell death in Caenorhabditis elegans . Dev Cell. 2007;12:73-86. (Pubitemid 46002599)
9. Yuan J, Kroemer G. Alternative cell death mechanisms in development and beyond. Genes Dev. 2010;24:2592-602.
10. Liu J, Tang TS, Tu H, Nelson O, Herndon E, Huynh DP, et al. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2. J Neurosci. 2009;29:9148-62.
11. Chen X, Tang TS, Tu H, Nelson O, Pook M, Hammer R, et al. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3. J Neurosci. 2008;28:12713-24.
12. Custer SK, Garden GA, Gill N, Rueb U, Libby RT, Schultz C, et al. Bergmann glia expression of polyglutamine-expanded ataxin-7 produces neurodegeneration by impairing glutamate transport. Nat Neurosci. 2006;9:1302-11. (Pubitemid 44454272)
13. Maltecca F, Magnoni R, Cerri F, Cox GA, Quattrini A, Casari G. Haploinsufficiency of AFG3L2, the gene responsible for spinocerebellar ataxia type 28, causes mitochondria-mediated Purkinje cell dark degeneration. J Neurosci. 2009;29:9244-54.
14. Oppenheim RW, Flavell RA, Vinsant S, Prevette D, Kuan CY, Rakic P. Programmed cell death of developing mammalian neurons after genetic deletion of caspases. J Neurosci. 2001;21:4752-60. (Pubitemid 32565633)
15. Blum ES, AbrahamMC, Yoshimura S, Lu Y, Shaham S. Control of nonapoptotic developmental cell death in Caenorhabditis elegans by a polyglutamine-repeat protein. Science. 2012;335:970-3.
16. Blum ES, Schwendeman AR, Shaham S. PolyQ disease: misfiring of a developmental cell death program? Trends Cell Biol. 2013;23:168-74.
17. Orr HT. Cell biology of spinocerebellar ataxia. J Cell Biol. 2012;197:167-77.
18. Chakrabarti L, Eng J, Ivanov N, Garden GA, La Spada AR. Autophagy activation and enhanced mitophagy characterize the Purkinje cells of pcd mice prior to neuronal death. Mol Brain. 2009;2:24.
19. Strahlendorf J, Box C, Attridge J, Diertien J, Finckbone V, Henne WM, et al. AMPA-induced dark cell degeneration of cerebellar Purkinje neurons involves activation of caspases and apparent mitochondrial dysfunction. Brain Res. 2003;994:146-59. (Pubitemid 37464878)
20. Barenberg P, Strahlendorf H, Strahlendorf J. Hypoxia induces an excitotoxic-type of dark cell degeneration in cerebellar Purkinje neurons. Neurosci Res. 2001;40:245-54. (Pubitemid 32633837)
21. Kasumu A, Bezprozvanny I. Deranged calcium signaling in Purkinje cells and pathogenesis in spinocerebellar ataxia 2 (SCA2) and other ataxias. Cerebellum. 2012;11:630-9.
22. Kasumu AW, Hougaard C, Rode F, Jacobsen TA, Sabatier JM, Eriksen BL, et al. Selective positive modulator of calcium-activated potassium channels exerts beneficial effects in a mouse model of spinocerebellar ataxia type 2. Chem Biol. 2012;19:1340-53.
23. Matilla-Dueñas A, Goold R, Giunti P. Molecular pathogenesis of spinocerebellar ataxias. Brain. 2006;129:1357-70.
24. Durr A. Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol. 2010;9:885-94.
25. FriedmanMJ, Shah AG, Fang ZH,Ward EG,Warren ST, Li S, et al. Polyglutamine domain modulates the TBP-TFIIB interaction: implications for its normal function and neurodegeneration. Nat Neurosci. 2007;10:1519-28. (Pubitemid 350175880)
26. Goold R, Hubank M, Hunt A, Holton J, Menon RP, Revesz T, et al. Down-regulation of the dopamine receptor D2 in mice lacking ataxin 1. Hum Mol Genet. 2007;16:2122-34. (Pubitemid 47354895)
27. Crespo-Barreto J, Fryer JD, Shaw CA, Orr HT, Zoghbi HY. Partial loss of ataxin-1 function contributes to transcriptional dysregulation in spinocerebellar ataxia type 1 pathogenesis. PLoS Genet. 2010;6: e1001021.
28. Matilla-Dueñas A, Sanchez I, Corral-Juan M, Davalos A, Alvarez R, Latorre P. Cellular and molecular pathways triggering neurodegeneration in the spinocerebellar ataxias. Cerebellum. 2010;9: 148-66.
29. Orr HT. Nuclear ataxias. Cold Spring Harb Perspect Biol. 2010;2: a000786.
30. Matilla-Dueñas A. The ever expanding spinocerebellar ataxias. Editorial. Cerebellum. 2012;11:821-7.
31. Sanchez I, Piñol P, Corral-Juan M, Pandolfo M, Matilla-Dueñas A. A novel function of Ataxin-1 in the modulation of PP2A activity is dysregulated in the spinocerebellar ataxia type 1. Hum Mol Genet. 2013;22:3425-37.
32. McCullough SD, Grant PA. Histone acetylation, acetyltransferases, and ataxia-alteration of histone acetylation and chromatin dynamics is implicated in the pathogenesis of polyglutamine-expansion disorders. Adv Protein Chem Struct Biol. 2010;79:165-203.
33. Smith KT, Workman JL. Introducing the acetylome. Nat Biotechnol. 2009;27:917-9.
34. Matilla-Dueñas A, Goold R, Giunti P. Clinical, genetic, molecular, and pathophysiological insights into spinocerebellar ataxia type 1. Cerebellum. 2008;7:106-14.
35. Mushegian AR, Bassett Jr DE, Boguski MS, Bork P, Koonin EV. Positionally cloned human disease genes: patterns of evolutionary conservation and functional motifs. Proc Natl Acad Sci U S A. 1997;94:5831-6
36. de Chiara C, Giannini C, Adinolfi S, de Boer J, Guida S, Ramos A, et al. The AXH module: an independently folded domain common to ataxin-1 and HBP1. FEBS Lett. 2003;551:107-12.
37. Chen YW, Allen MD, Veprintsev DB, Lowe J, Bycroft M. The structure of the AXH domain of spinocerebellar ataxin-1. J Biol Chem. 2004;279:3758-65
38. de Chiara C, Menon RP, Adinolfi S, de Boer J, Ktistaki E, Kelly G, et al. The AXH domain adopts alternative folds the solution structure of HBP1 AXH. Structure (Camb). 2005;13:743-53.
39. Yue S, Serra HG, Zoghbi HY, Orr HT. The spinocerebellar ataxia type 1 protein, ataxin-1, has RNA-binding activity that is inversely affected by the length of its polyglutamine tract. Hum Mol Genet. 2001;10:25-30. (Pubitemid 32051564)
40. Lim J, Hao T, Shaw C, Patel AJ, Szabo G, Rual JF, et al. A protein- protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration. Cell. 2006;125:801-14. (Pubitemid 43732348)
41. Matilla A, Koshy BT, Cummings CJ, Isobe T, Orr HT, Zoghbi HY. The cerebellar leucine-rich acidic nuclear protein interacts with ataxin-1. Nature. 1997;389:974-8. (Pubitemid 27485689)
42. Bowman AB, Lam YC, Jafar-Nejad P, Chen HK, Richman R, Samaco RC, et al. Duplication of Atxn1l suppresses SCA1 neuropathology by decreasing incorporation of polyglutamine-expanded ataxin-1 into native complexes. Nat Genet. 2007;39:373-9. (Pubitemid 46328494)
43. Tong X, Gui H, Jin F, Heck BW, Lin P, Ma J, et al. Ataxin-1 and Brother of ataxin-1 are components of the Notch signalling pathway. EMBO Rep. 2011;12:428-35.
44. Lam YC, Bowman AB, Jafar-Nejad P, Lim J, Richman R, Fryer JD, et al. ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology. Cell. 2006;127:1335-47. (Pubitemid 44960413)
45. Tsuda H, Jafar-Nejad H, Patel AJ, Sun Y, Chen HK, RoseMF, et al. The AXH domain of ataxin-1 mediates neurodegeneration through its interaction with Gfi-1/Senseless proteins. Cell. 2005;122:633 - 44.
46. Tsai CC, Kao HY, Mitzutani A, Banayo E, Rajan H, McKeown M, et al. Ataxin 1, a SCA1 neurodegenerative disorder protein, is functionally linked to the silencing mediator of retinoid and thyroid hormone receptors. Proc Natl Acad Sci U S A. 2004;101:4047-52. (Pubitemid 38405881)
47. Okazawa H, Rich T, Chang A, Lin X, Waragai M, Kajikawa M, et al. Interaction between mutant ataxin-1 and PQBP-1 affects transcription and cell death. Neuron. 2002;34:701-13. (Pubitemid 34628734)
48. Serra HG, Duvick L, Zu T, Carlson K, Stevens S, Jorgensen N, et al. RORalpha-mediated Purkinje cell development determines disease severity in adult SCA1 mice. Cell. 2006;127:697-708. (Pubitemid 44716252)
49. Lim J, Crespo-Barreto J, Jafar-Nejad P, Bowman AB, Richman R, Hill DE, et al. Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1. Nature. 2008;452: 713-8
50. de Chiara C, Menon RP, Strom M, Gibson TJ, Pastore A. Phosphorylation of S776 and 14-3-3 binding modulate ataxin-1 interaction with splicing factors. PLoS One. 2009;4:e8372.
51. Fernandez-Funez P, Nino-Rosales ML, de Gouyon B, She WC, Luchak JM, Martinez P, et al. Identification of genes that modify ataxin-1-induced neurodegeneration. Nature. 2000;408:101-6.
52. Mizutani A, Wang L, Rajan H, Vig PJ, Alaynick WA, Thaler JP, et al. Boat, an AXH domain protein, suppresses the cytotoxicity of mutant ataxin-1. EMBO J. 2005;24:3339-51. (Pubitemid 41348707)
53. Gehrking KM, Andresen JM, Duvick L, Lough J, Zoghbi HY, Orr HT. Partial loss of Tip60 slows mid-stage neurodegeneration in a spinocerebellar ataxia type 1 (SCA1) mouse model. Hum Mol Genet. 2011;20:2204-12.
54. Serra HG, Byam CE, Lande JD, Tousey SK, Zoghbi HY, Orr HT. Gene profiling links SCA1 pathophysiology to glutamate signaling in Purkinje cells of transgenic mice. Hum Mol Genet. 2004;13: 2535-43. (Pubitemid 39377856)
55. Ciani L, Salinas PC. WNTs in the vertebrate nervous system: from patterning to neuronal connectivity. Nat Rev Neurosci. 2005;6:351 - 62.
56. Glover JC, Renaud JS, Rijli FM. Retinoic acid and hindbrain patterning. J Neurobiol. 2006;66:705-25. (Pubitemid 43939195)
57. Fryer JD, Yu P, Kang H, Mandel-Brehm C, Carter AN, Crespo-Barreto J, et al. Exercise and genetic rescue of SCA1 via the transcriptional repressor Capicua. Science. 2011;334:690-3.
58. Ralser M, Albrecht M, Nonhoff U, Lengauer T, Lehrach H, Krobitsch S. An integrative approach to gain insights into the cellular function of human ataxin-2. J Mol Biol. 2005;346:203-14. (Pubitemid 40128315)
59. Nonis D, Schmidt MH, van de Loo S, Eich F, Dikic I, Nowock J, et al. Ataxin-2 associates with the endocytosis complex and affects EGF receptor trafficking. Cell Signal. 2008;20:1725-39.
60. Lastres-Becker I, Rub U, Auburger G. Spinocerebellar ataxia 2 (SCA2). Cerebellum. 2008;7:115-24.
61. Satterfield TF, Pallanck LJ. Ataxin-2 and its Drosophila homolog, ATX2, physically assemble with polyribosomes. Hum Mol Genet. 2006;15:2523-32. (Pubitemid 44288704)
62. Hallen L, Klein H, Stoschek C, Wehrmeyer S, Nonhoff U, Ralser M, et al. The KRAB-containing zinc-finger transcriptional regulator ZBRK1 activates SCA2 gene transcription through direct interaction with its gene product, ataxin-2. Hum Mol Genet. 2011;20:104 - 14.
63. Urrutia R. KRAB-containing zinc-finger repressor proteins. Genome Biol. 2003;4:231.
64. Shimohata T, Nakajima T, Yamada M, Uchida C, Onodera O, Naruse S, et al. Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat Genet. 2000;26:29-36.
65. Takahashi J, Tanaka J, Arai K, Funata N, Hattori T, Fukuda T, et al. Recruitment of nonexpanded polyglutamine proteins to intranuclear aggregates in neuronal intranuclear hyaline inclusion disease. J Neuropathol Exp Neurol. 2001;60:369-76. (Pubitemid 32274052)
66. McCampbell A, Taylor JP, Taye AA, Robitschek J, LiM,Walcott J, et al. CREB-binding protein sequestration by expanded polyglutamine. Hum Mol Genet. 2000;9:2197-202.
67. Chai Y, Shao J, Miller VM, Williams A, Paulson HL. Live-cell imaging reveals divergent intracellular dynamics of polyglutamine disease proteins and supports a sequestrationmodel of pathogenesis. Proc Natl Acad Sci U S A. 2002;99:9310-5. (Pubitemid 34764610)
68. Wang G, Sawai N, Kotliarova S, Kanazawa I, Nukina N. Ataxin-3, the MJD1 gene product, interacts with the two human homologs of yeast DNA repair protein RAD23, HHR23A and HHR23B. Hum Mol Genet. 2000;9:1795-803. (Pubitemid 30608613)
69. Evert BO, Araujo J, Vieira-Saecker AM, de Vos RA, Harendza S, Klockgether T, et al. Ataxin-3 represses transcription via chromatin binding, interaction with histone deacetylase 3, and histone deacetylation. J Neurosci. 2006;26:11474-86. (Pubitemid 44772178)
70. Costa Mdo C, Paulson HL. Toward understanding Machado- Joseph disease. Prog Neurobiol. 2012;97:239-57.
71. Evert BO, Vogt IR, Vieira-Saecker AM, Ozimek L, de Vos RA, Brunt ER, et al. Gene expression profiling in ataxin-3 expressing cell lines reveals distinct effects of normal and mutant ataxin-3. J Neuropathol Exp Neurol. 2003;62:1006-18. (Pubitemid 37229531)
72. Araujo J, Breuer P, Dieringer S, Krauss S, Dorn S, Zimmermann K, et al. FOXO4-dependent upregulation of superoxide dismutase-2 in response to oxidative stress is impaired in spinocerebellar ataxia type 3. Hum Mol Genet. 2011;20:2928-41.
73. Helmlinger D, Hardy S, Abou-Sleymane G, Eberlin A, Bowman AB, Gansmüller A, et al. Glutamine-expanded ataxin-7 alters TFTC/STAGA recruitment and chromatin structure leading to photoreceptor dysfunction. PLoS Biol. 2006;4:e67.
74. Samara NL, Wolberger C. A new chapter in the transcription SAGA. Curr Opin Struct Biol. 2011;21:767-74.
75. Chen YC, Gatchel JR, Lewis RW, Mao CA, Grant PA, Zoghbi HY, et al. Gcn5 loss-of-function accelerates cerebellar and retinal degeneration in a SCA7 mouse model. Hum Mol Genet. 2011;21:394 - 405.
76. Koide R, Kobayashi S, Shimohata T, Ikeuchi T,Maruyama M, Saito M, et al. A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA-binding protein gene: a new polyglutamine disease? Hum Mol Genet. 1999;8:2047-53. (Pubitemid 29458732)
77. Nakamura K, Jeong SY, Uchihara T, Anno M, Nagashima K, Nagashima T, et al. SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum Mol Genet. 2001;10:1441-8. (Pubitemid 32684885)
78. Kalmar B, Greensmith L. Induction of heat shock proteins for protection against oxidative stress. Adv Drug Deliv Rev. 2009;61: 310-8.
79. Williams AJ, Paulson HL. Polyglutamine neurodegeneration: protein misfolding revisited. Trends Neurosci. 2008;31:521-8.
80. Arawaka S, Machiya Y, Kato T. Heat shock proteins as suppressors of accumulation of toxic prefibrillar intermediates and misfolded proteins in neurodegenerative diseases. Curr Pharm Biotechnol. 2010;11:158-66.
81. Sajjad MU, Samson B, Wyttenbach A. Heat shock proteins: therapeutic drug targets for chronic neurodegeneration? Curr Pharm Biotechnol. 2010;11:198-215.
82. Gautier T, Berges T, Tollervey D, Hurt E. Nucleolar KKE/D repeat proteins Nop56p and Nop58p interact with Nop1p and are required for ribosome biogenesis. Mol Cell Biol. 1997;17:7088-98. (Pubitemid 27505938)
83. Kobayashi H, Abe K, Matsuura T, Ikeda Y, Hitomi T, Akechi Y, et al. Expansion of intronic GGCCTG hexanucleotide repeat in NOP56 causes SCA36, a type of spinocerebellar ataxia accompanied by motor neuron involvement. Am J Hum Genet. 2011;89: 121-30.
84. Zhang S, Xu L, Lee J, Xu T. Drosophila atrophin homolog functions as a transcriptional corepressor in multiple developmental processes. Cell. 2002;108:45-56. (Pubitemid 34137011)
85. Wang L, Rajan H, Pitman JL, McKeown M, Tsai CC. Histone deacetylase-associating atrophin proteins are nuclear receptor core-pressors. Genes Dev. 2006;20:525-30. (Pubitemid 43345318)
86. Shen Y, Lee G, Choe Y, Zoltewicz JS, Peterson AS. Functional architecture of atrophins. J Biol Chem. 2007;282:5037-44. (Pubitemid 47100924)
87. Wang L, Tsai CC. Atrophin proteins: an overview of a new class of nuclear receptor corepressors. Nucl Recept Signal. 2008;6:e009.
88. Wood JD, Nucifora Jr FC, Duan K, Zhang C,Wang J, Kim Y, et al. Atrophin-1, the dentato-rubral and pallido-luysian atrophy gene product, interacts with ETO/MTG8 in the nuclear matrix and represses transcription. J Cell Biol. 2000;150:939-48.
89. Napoletano F, Occhi S, Calamita P, Volpi V, Blanc E, Charroux B, et al. Polyglutamine atrophin provokes neurodegeneration in Drosophila by repressing fat. EMBO J. 2011;30:945-58.
90. Lin X, Antalffy B, Kang D, Orr HT, Zoghbi HY. Polyglutamine expansion down-regulates specific neuronal genes before pathologic changes in SCA1. Nat Neurosci. 2000;3:157-63. (Pubitemid 30126331)
91. Wiegert JS, Bading H. Activity-dependent calcium signaling and ERK-MAP kinases in neurons: a link to structural plasticity of the nucleus and gene transcription regulation. Cell Calcium. 2011;49: 296-305.
92. Bilen J, Liu N, Bonini NM. A new role for microRNA pathways: modulation of degeneration induced by pathogenic human disease proteins. Cell Cycle. 2006;5:2835-8. (Pubitemid 44953931)
93. Karres JS, Hilgers V, Carrera I, Treisman J, Cohen SM. The conserved microRNA miR-8 tunes atrophin levels to prevent neurodegeneration in Drosophila . Cell. 2007;131:136-45. (Pubitemid 47498538)
94. Lee Y, Samaco RC, Gatchel JR, Thaller C, Orr HT, Zoghbi HY. miR-19, miR-101 and miR-130 co-regulate ATXN1 levels to potentially modulate SCA1 pathogenesis. Nat Neurosci. 2008;11: 1137-9.
95. Persengiev S, Kondova I, Otting N, Koeppen AH, Bontrop RE. Genome-wide analysis of miRNA expression reveals a potential role for miR-144 in brain aging and spinocerebellar ataxia pathogenesis. Neurobiol Aging. 2011;32(2316):e17-27.
96. DiFigliaM, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 1997;277:1990-3.
97. Paulson HL, Perez MK, Trottier Y, Trojanowski JQ, Subramony SH, Das SS, et al. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron. 1997;19:333-44. (Pubitemid 27374232)
98. Skinner PJ, Koshy BT, Cummings CJ, Klement IA, Helin K, Servadio A, et al. Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures. Nature. 1997;389:971-4. (Pubitemid 27485688)
99. Becher MW, Kotzuk JA, Sharp AH, Davies SW, Bates GP, Price DL, et al. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol Dis. 1998;4:387-97. (Pubitemid 28201657)
100. Holmberg M, Duyckaerts C, Durr A, Cancel G, Gourfinkel-An I, Damier P, et al. Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions. Hum Mol Genet. 1998;7:913-8. (Pubitemid 28221256)
101. Li M, Miwa S, Kobayashi Y, Merry DE, Yamamoto M, Tanaka F, et al. Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy. Ann Neurol. 1998;44:249-54. (Pubitemid 28374114)
102. Schmidt T, Landwehrmeyer GB, Schmitt I, Trottier Y, Auburger G, Laccone F, et al. An isoform of ataxin-3 accumulates in the nucleus of neuronal cells in affected brain regions of SCA3 patients. Brain Pathol. 1998;8:669-79. (Pubitemid 28460926)
103. Huynh DP, Del Bigio MR, Ho DH, Pulst SM. Expression of ataxin- 2 in brains from normal individuals and patients with Alzheimer's disease and spinocerebellar ataxia 2. Ann Neurol. 1999;45:232-41. (Pubitemid 29072370)
104. Koyano S, Uchihara T, Fujigasaki H, Nakamura A, Yagishita S, Iwabuchi K. Neuronal intranuclear inclusions in spinocerebellar ataxia type 2: triple-labeling immunofluorescent study. Neurosci Lett. 1999;273:117-20. (Pubitemid 29428121)
105. Ishikawa K, Fujigasaki H, Saegusa H, Ohwada K, Fujita T, Iwamoto H, et al. Abundant expression and cytoplasmic aggregations of [alpha]1A voltage-dependent calcium channel protein associated with neurodegeneration in spinocerebellar ataxia type 6. Hum Mol Genet. 1999;8:1185-93. (Pubitemid 29328986)
106. Munch C, Bertolotti A. Propagation of the prion phenomenon: beyond the seeding principle. J Mol Biol. 2012;421:491-8.
107. Freundt EC, Maynard N, Clancy EK, Roy S, Bousset L, Sourigues Y, et al. Neuron-to-neuron transmission of alpha-synuclein fibrils through axonal transport. Ann Neurol. 2012;72:517-24.
108. Yang W, Dunlap JR, Andrews RB, Wetzel R. Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum Mol Genet. 2002;11:2905-17.
109. Ren PH, Lauckner JE, Kachirskaia I, Heuser JE, Melki R, Kopito RR. Cytoplasmic penetration and persistent infection ofmammalian cells by polyglutamine aggregates. Nat Cell Biol. 2009;11:219-25.
110. Daughters RS, Tuttle DL, GaoW, Ikeda Y, MoseleyML, Ebner TJ, et al. RNA gain-of-function in spinocerebellar ataxia type 8. PLoS Genet. 2009;5:e1000600.
111. Seidel K, Siswanto S, Brunt ER, den Dunnen W, Korf HW, Rub U. Brain pathology of spinocerebellar ataxias. Acta Neuropathol. 2012;124:1-21.
112. Houlden H, Johnson J, Gardner-Thorpe C, Lashley T, Hernandez D, Worth P, et al.Mutations in TTBK2, encoding a kinase implicated in tau phosphorylation, segregate with spinocerebellar ataxia type 11. Nat Genet. 2007;39:1434-6. (Pubitemid 350191351)
113. Perutz MF, Johnson T, Suzuki M, Finch JT. Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci U S A. 1994;91:5355-8. (Pubitemid 24174325)
114. Ikeda H, Yamaguchi M, Sugai S, Aze Y, Narumiya S, Kakizuka A. Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo.Nat Genet. 1996;13:196-202. (Pubitemid 26000440)
115. Mangiarini L, Sathasivam K, Mahal A, Mott R, Seller M, Bates GP. Instability of highly expanded CAG repeats in mice transgenic for the Huntington's disease mutation. Nat Genet. 1997;15:197-200. (Pubitemid 27061643)
116. Cowan KJ, Diamond MI, Welch WJ. Polyglutamine protein aggregation and toxicity are linked to the cellular stress response. Hum Mol Genet. 2003;12:1377-91. (Pubitemid 36758451)
117. Gusella JF, MacDonald ME. Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. Nat Rev Neurosci. 2000;1:109-15.
118. Sieradzan KA, Mechan AO, Jones L, Wanker EE, Nukina N, Mann DM. Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Exp Neurol. 1999;156:92-9. (Pubitemid 29152986)
119. Garden GA, Libby RT, Fu YH, Kinoshita Y, Huang J, Possin DE, et al. Polyglutamine-expanded ataxin-7 promotes non-cell-autonomous Purkinje cell degeneration and displays proteolytic cleavage in ataxic transgenic mice. J Neurosci. 2002;22:4897-905. (Pubitemid 37465605)
120. Goti D, Katzen SM, Mez J, Kurtis N, Kiluk J, Ben-Haiem L, et al. A mutant ataxin-3 putative-cleavage fragment in brains of Machado- Joseph disease patients and transgenic mice is cytotoxic above a critical concentration. J Neurosci. 2004;24:10266-79. (Pubitemid 39492054)
121. Wellington CL, Ellerby LM, Hackam AS, Margolis RL, Trifiro MA, Singaraja R, et al. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem. 1998;273:9158-67. (Pubitemid 28176206)
122. Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, Lu G, et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell. 2006;125: 1179-91. (Pubitemid 43866195)
123. Haacke A, Hartl FU, Breuer P. Calpain inhibition is sufficient to suppress aggregation of polyglutamine-expanded ataxin-3. J Biol Chem. 2007;282:18851-6. (Pubitemid 47100145)
124. Young JE, Gouw L, Propp S, Sopher BL, Taylor J, Lin A, et al. Proteolytic cleavage of ataxin-7 by caspase-7 modulates cellular toxicity and transcriptional dysregulation. J Biol Chem. 2007;282: 30150-60. (Pubitemid 350035251)
125. Hubener J,Weber JJ, Richter C, Honold L,Weiss A,Murad F, et al. Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3). Hum Mol Genet. 2013;22: 508-18.
126. Simoes AT, Goncalves N, Koeppen A, Deglon N, Kugler S, Duarte CB, et al. Calpastatin-mediated inhibition of calpains in the mouse brain prevents mutant ataxin 3 proteolysis, nuclear localization and aggregation, relieving Machado-Joseph disease. Brain. 2012;135: 2428-39.
127. Masino L, Nicastro G, Menon RP, Dal Piaz F, Calder L, Pastore A. Characterization of the structure and the amyloidogenic properties of the Josephin domain of the polyglutamine-containing protein ataxin-3. J Mol Biol. 2004;344:1021-35. (Pubitemid 39491247)
128. Ellisdon AM, Thomas B, Bottomley SP. The two-stage pathway of ataxin-3 fibrillogenesis involves a polyglutamine-independent step. J Biol Chem. 2006;281:16888-96.
129. Hubener J, Vauti F, Funke C, Wolburg H, Ye Y, Schmidt T, et al. N-terminal ataxin-3 causes neurological symptoms with inclusions, endoplasmic reticulum stress and ribosomal dislocation. Brain. 2011;134:1925-42.
130. Perez MK, Paulson HL, Pendse SJ, Saionz SJ, Bonini NM, Pittman RN. Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation. J Cell Biol. 1998;143: 1457-70. (Pubitemid 29006496)
131. Fujigasaki H, Uchihara T, Koyano S, Iwabuchi K, Yagishita S, Makifuchi T, et al. Ataxin-3 is translocated into the nucleus for the formation of intranuclear inclusions in normal and Machado- Joseph disease brains. Exp Neurol. 2000;165:248-56.
132. Uchihara T, Fujigasaki H, Koyano S, Nakamura A, Yagishita S, Iwabuchi K. Non-expanded polyglutamine proteins in intranuclear inclusions of hereditary ataxias-triple-labeling immunofluorescence study. Acta Neuropathol. 2001;102:149-52. (Pubitemid 32771662)
133. Chai Y, Wu L, Griffin JD, Paulson HL. The role of protein composition in specifying nuclear inclusion formation in polyglutamine disease. J Biol Chem. 2001;276:44889-97.
134. Zander C, Takahashi J, El Hachimi KH, Fujigasaki H, Albanese V, Lebre AS, et al. Similarities between spinocerebellar ataxia type 7 (SCA7) cell models and human brain: proteins recruited in inclusions and activation of caspase-3. Hum Mol Genet. 2001;10:2569-79. (Pubitemid 33095007)
135. Schmidt T, Lindenberg KS, Krebs A, Schols L, Laccone F, Herms J, et al. Protein surveillance machinery in brains with spinocerebellar ataxia type 3: redistribution and differential recruitment of 26S proteasome subunits and chaperones to neuronal intranuclear inclusions. Ann Neurol. 2002;51:302-10. (Pubitemid 34206286)
136. Verhoef LG, Lindsten K, Masucci MG, Dantuma NP. Aggregate formation inhibits proteasomal degradation of polyglutamine proteins. Hum Mol Genet. 2002;11:2689-700.
137. Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin- proteasome system by protein aggregation. Science. 2001;292: 1552-5. (Pubitemid 32493425)
138. Waelter S, Boeddrich A, Lurz R, Scherzinger E, Lueder G, Lehrach H, et al. Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol Biol Cell. 2001;12:1393-407. (Pubitemid 33044419)
139. Zhou H, Cao F, Wang Z, Yu ZX, Nguyen HP, Evans J, et al. Huntingtin forms toxic NH2-terminal fragment complexes that are promoted by the age-dependent decrease in proteasome activity. J Cell Biol. 2003;163:109-18. (Pubitemid 37271438)
140. Petroi D, Popova B, Taheri-Talesh N, Irniger S, Shahpasandzadeh H, Zweckstetter M, et al. Aggregate clearance of alpha-synuclein in Saccharomyces cerevisiae depends more on autophagosome and vacuole function than on the proteasome. J Biol Chem. 2012;287: 27567-79.
141. Sisodia SS. Nuclear inclusions in glutamine repeat disorders: are they pernicious, coincidental, or beneficial? Cell. 1998;95:1-4. (Pubitemid 28458015)
142. Adachi H, Katsuno M, Minamiyama M, Waza M, Sang C, Nakagomi Y, et al. Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients. Brain. 2005;128:659-70. (Pubitemid 40380200)
143. Klement IA, Skinner PJ, Kaytor MD, Yi H, Hersch SM, Clark HB, et al. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell. 1998;95:41-53. (Pubitemid 28458023)
144. Saudou F, Finkbeiner S, Devys D, Greenberg ME. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell. 1998;95:55-66.
145. Kretzschmar D, Tschape J, Bettencourt Da Cruz A, Asan E, Poeck B, Strauss R, et al. Glial and neuronal expression of polyglutamine proteins induce behavioral changes and aggregate formation in Drosophila . Glia. 2005;49:59-72. (Pubitemid 40023653)
146. Boy J, Schmidt T, Schumann U, Grasshoff U, Unser S, Holzmann C, et al. A transgenic mouse model of spinocerebellar ataxia type 3 resembling late disease
147. Weiss A, Klein C, Woodman B, Sathasivam K, Bibel M, Regulier E, et al. Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease. J Neurochem. 2008;104:846-58.
148. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature. 2002;416:507-11. (Pubitemid 34288846)
149. Takahashi T, Nozaki K, Tsuji S, Nishizawa M, Onodera O. Polyglutamine represses cAMP-responsive-element-mediated transcription without aggregate formation. Neuroreport. 2005;16:295-9. (Pubitemid 40364594)
150. Chafekar SM, Wisen S, Thompson AD, Echeverria A, Walter GM, Evans CG, et al. Pharmacological tuning of heat shock protein 70 modulates polyglutamine toxicity and aggregation. ACS Chem Biol. 2012;7:1556-64.
151. Bauer PO, Goswami A, Wong HK, Okuno M, Kurosawa M, Yamada M, et al. Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein. Nat Biotechnol. 2010;28:256-63.
152. Menzies FM, Huebener J, Renna M, Bonin M, Riess O, Rubinsztein DC. Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3. Brain. 2010;133:93-104.
153. Klionsky DJ. Autophagy: from phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol. 2007;8: 931-7. (Pubitemid 47622558)
154. Scherz-Shouval R, Shvets E, Fass E, Shorer H, Gil L, Elazar Z. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. EMBO J. 2007;26:1749-60. (Pubitemid 46624042)
155. Ravikumar B, Duden R, Rubinsztein DC. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum Mol Genet. 2002;11:1107-17. (Pubitemid 34521091)
156. Yang Z, Klionsky DJ. An overview of the molecular mechanism of autophagy. Curr Top Microbiol Immunol. 2009;335:1-32.
157. Ganley IG, du Lam H, Wang J, Ding X, Chen S, Jiang X. ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy. J Biol Chem. 2009;284:12297-305.
158. Blommaart EF, Krause U, Schellens JP, Vreeling-Sindelarova H, Meijer AJ. The phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 inhibit autophagy in isolated rat hepatocytes. Eur J Biochem. 1997;243:240-6. (Pubitemid 27060408)
159. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy. 2008;4: 151-75. (Pubitemid 351231180)
160. Yamamoto A, Tagawa Y, Yoshimori T, Moriyama Y, Masaki R, Tashiro Y. Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct Funct. 1998;23: 33-42. (Pubitemid 28223394)
161. Ravikumar B, Sarkar S, Davies JE, Futter M, Garcia-Arencibia M, Green-Thompson ZW, et al. Regulation of mammalian autophagy in physiology and pathophysiology. Physiol Rev. 2010;90:1383-435.
162. Hara T, Nakamura K, Matsui M,Yamamoto A, Nakahara Y, Suzuki-Migishima R, et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature. 2006;441:885-9.
163. Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature. 2006;441:880-4.
164. Winslow AR, Chen CW, Corrochano S, Acevedo-Arozena A, Gordon DE, Peden AA, et al. Alpha-synuclein impairs macroautophagy: implications for Parkinson's disease. J Cell Biol. 2010;190:1023-37.
165. Ju JS, Fuentealba RA, Miller SE, Jackson E, Piwnica-Worms D, Baloh RH, et al. Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease. J Cell Biol. 2009;187: 875-88.
166. Fukuda T, Ewan L, Bauer M, Mattaliano RJ, Zaal K, Ralston E, et al. Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease. Ann Neurol. 2006;59:700-8.
167. Sanchez-Varo R, Trujillo-Estrada L, Sanchez-Mejias E, Torres M, Baglietto-Vargas D, Moreno-Gonzalez I, et al. Abnormal accumulation of autophagic vesicles correlates with axonal and synaptic pathology in young Alzheimer 's mice hippocampus. Acta Neuropathol. 2012;123:53-70.
168. Martinez-Vicente M, Talloczy Z, Wong E, Tang G, Koga H, Kaushik S, et al. Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease. Nat Neurosci. 2010;13: 567-76.
169. Durcan TM, Fon EA. Mutant ataxin-3 promotes the autophagic degradation of parkin. Autophagy. 2011;7:233-4.
170. Berger Z, Ravikumar B, Menzies FM, Oroz LG, Underwood BR, Pangalos MN, et al. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet. 2006;15:433-42. (Pubitemid 43159895)
171. Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC. Alpha-synuclein is degraded by both autophagy and the proteasome. J Biol Chem. 2003;278:25009-13. (Pubitemid 37548663)
172. Lunemann JD, Schmidt J, Schmid D, Barthel K, Wrede A, Dalakas MC, et al. Beta-amyloid is a substrate of autophagy in sporadic inclusion body myositis. Ann Neurol. 2007;61:476-83. (Pubitemid 46878775)
173. Williams A, Sarkar S, Cuddon P, Ttofi EK, Saiki S, Siddiqi FH, et al. Novel targets for Huntington 's disease in an mTOR-independent autophagy pathway. Nat Chem Biol. 2008;4:295-305. (Pubitemid 351550888)
174. Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet. 2004;36:585-95. (Pubitemid 38715985)
175. Caccamo A, Majumder S, Richardson A, Strong R, Oddo S. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and tau: effects on cognitive impairments. J Biol Chem. 2010;285:13107-20.
176. Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, Bredesen D, et al. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer 's disease. PLoS One. 2010;5:e9979.
177. Spencer B, Potkar R, Trejo M, Rockenstein E, Patrick C, Gindi R, et al. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases. J Neurosci. 2009;29:13578-88.
178. Bilen J, Bonini NM. Genome-wide screen for modifiers of ataxin-3 neurodegeneration in Drosophila . PLoS Genet. 2007;3:1950-64. (Pubitemid 350072059)
179. Yamamoto K, Seki T, Adachi N, Takahashi T, Tanaka S, Hide I, et al. Mutant protein kinase C gamma that causes spinocerebellar ataxia type 14 (SCA14) is selectively degraded by autophagy. Genes Cells. 2010;15:425-38.
180. Yu X, Ajayi A, Boga NR, Strom AL. Differential degradation of full-length and cleaved ataxin-7 fragments in a novel stable inducible SCA7 model. J Mol Neurosci. 2012;47:219-33.
181. Mookerjee S, Papanikolaou T, Guyenet SJ, Sampath V, Lin A, Vitelli C, et al. Posttranslational modification of ataxin-7 at lysine 257 prevents autophagy-mediated turnover of an N-terminal caspase-7 cleavage fragment. J Neurosci. 2009;29:15134-44.
182. Nascimento-Ferreira I, Santos-Ferreira T, Sousa-Ferreira L, Auregan G, Onofre I, Alves S, et al. Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machado-Joseph disease. Brain. 2011;134:1400-15.
183. Grewer C, Rauen T. Electrogenic glutamate transporters in the CNS: molecular mechanism, pre-steady-state kinetics, and their impact on synaptic signaling. J Membr Biol. 2005;203:1-20. (Pubitemid 40576957)
184. Ramamoorthy S, Leibach FH, Mahesh VB, Ganapathy V. Active transport of dopamine in human placental brush-border membrane vesicles. Am J Physiol. 1992;262:C1189-96.
185. Fahlke C. Molecular mechanisms of ion conduction in ClC-type chloride channels: lessons from disease-causing mutations. Kidney Int. 2000;57:780-6. (Pubitemid 30434766)
186. Thakker RV. Chloride channels in renal disease. Adv Nephrol Necker Hosp. 1999;29:289-98.
187. Zhuchenko O, Bailey J, Bonnen P, Ashizawa T, Stockton DW, Amos C, et al. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage- dependent calcium channel. Nat Genet. 1997;15:62-9.
188. Pulst SM, Santos N, Wang D, Yang H, Huynh D, Velazquez L, et al. Spinocerebellar ataxia type 2: polyQ repeat variation in the CACNA1A calcium channel modifies age of onset. Brain. 2005;128:2297-303. (Pubitemid 41407970)
189. Geschwind DH, Perlman S, Figueroa KP, Karrim J, Baloh RW, Pulst SM. Spinocerebellar ataxia type 6. Frequency of the mutation and genotype-phenotype correlations. Neurology. 1997;49: 1247-51. (Pubitemid 27495623)
190. Baloh RW. Episodic ataxias 1 and 2. Handb Clin Neurol. 2012;103: 595-602.
191. Jodice C, Mantuano E, Veneziano L, Trettel F, Sabbadini G, Calandriello L, et al. Episodic ataxia type 2 (EA2) and spinocerebellar ataxia type 6 (SCA6) due to CAG repeat expansion in the CACNA1A gene on chromosome 19p. Hum Mol Genet. 1997;6:1973-8. (Pubitemid 27460375)
192. Denier C, Ducros A, Vahedi K, Joutel A, Thierry P, Ritz A, et al. High prevalence of CACNA1A truncations and broader clinical spectrum in episodic ataxia type 2. Neurology. 1999;52:1816-21. (Pubitemid 29260894)
193. Walter JT, Alvina K, Womack MD, Chevez C, Khodakhah K. Decreases in the precision of Purkinje cell pacemaking cause cerebellar dysfunction and ataxia. Nat Neurosci. 2006;9:389-97. (Pubitemid 43290969)
194. Watase K, Barrett CF, Miyazaki T, Ishiguro T, Ishikawa K, Hu Y, et al. Spinocerebellar ataxia type 6 knockin mice develop a progressive neuronal dysfunction with age-dependent accumulation of mutant CaV2.1 channels. Proc Natl Acad Sci U S A. 2008;105: 11987-92.
195. Tonelli A, D'AngeloMG, Salati R, Villa L, Germinasi C, Frattini T, et al. Early onset, non fluctuating spinocerebellar ataxia and a novel missense mutation in CACNA1A gene. J Neurol Sci. 2006;241:13-7.
196. Jen J,Wan J, Graves M, Yu H, Mock AF, Coulin CJ, et al. Loss-of-function EA2 mutations are associated with impaired neuromuscular transmission. Neurology. 2001;57:1843-8. (Pubitemid 33096693)
197. Tottene A, Fellin T, Pagnutti S, Luvisetto S, Striessnig J, Fletcher C, et al. Familial hemiplegicmigrainemutations increase Ca(2+) influx through single human CaV2.1 channels and decrease maximal CaV2.1 current density in neurons. Proc Natl Acad Sci U S A. 2002;99:13284-9.
198. Mullner C, Broos LA, van den Maagdenberg AM, Striessnig J. Familial hemiplegic migraine type 1 mutations K1336E, W1684R, and V1696I alter Cav2.1 Ca2+ channel gating: evidence for beta-subunit isoform-specific effects. J Biol Chem. 2004;279:51844-50. (Pubitemid 39656551)
199. Ducros A, Denier C, Joutel A, Cecillon M, Lescoat C, Vahedi K, et al. The clinical spectrum of familial hemiplegic migraine associated with mutations in a neuronal calcium channel. N Engl J Med. 2001;345:17-24. (Pubitemid 32634267)
200. Waters MF, Fee D, Figueroa KP, Nolte D, Muller U, Advincula J, et al. An autosomal dominant ataxia maps to 19q13: allelic heterogeneity of SCA13 or novel locus? Neurology. 2005;65:1111-3. (Pubitemid 41429643)
201. Herman-Bert A, Stevanin G, Netter JC, Rascol O, Brassat D, Calvas P, et al. Mapping of spinocerebellar ataxia 13 to chromosome 19q13.3-q13.4 in a family with autosomal dominant cerebellar ataxia and mental retardation. Am J Hum Genet. 2000;67:229-35. (Pubitemid 30481561)
202. Waters MF, Minassian NA, Stevanin G, Figueroa KP, Bannister JP, Nolte D, et al. Mutations in voltage-gated potassium channel KCNC3 cause degenerative and developmental central nervous system phenotypes. Nat Genet. 2006;38:447-51.
203. Waters MF, Pulst SM. Sca13. Cerebellum. 2008;7:165-9.
204. Figueroa KP, Minassian NA, Stevanin G, Waters M, Garibyan V, Forlani S, et al. KCNC3: phenotype, mutations, channel biophysics - a study of 260 familial ataxia patients. Hum Mutat. 2010;31:191-6.
205. Figueroa KP, Waters MF, Garibyan V, Bird TD, Gomez CM, Ranum LP, et al. Frequency of KCNC3 DNA variants as causes of spinocerebellar ataxia 13 (SCA13). PLoS One. 2011;6:e17811.
206. Shakkottai VG, Chou CH, Oddo S, Sailer CA, Knaus HG, Gutman GA, et al. Enhanced neuronal excitability in the absence of neurodegeneration induces cerebellar ataxia. J Clin Invest. 2004;113: 582-90. (Pubitemid 38542507)
207. Figueroa KP, Chan P, Schols L, Tanner C, Riess O, Perlman SL, et al. Association of moderate polyglutamine tract expansions in the slow calcium-activated potassium channel type 3 with ataxia. Arch Neurol. 2001;58:1649-53. (Pubitemid 32963230)
208. Browne DL, Gancher ST, Nutt JG, Brunt ER, Smith EA, Kramer P, et al. Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNA1. Nat Genet. 1994;8:136-40. (Pubitemid 24308360)
209. D'AdamoMC, Imbrici P, Sponcichetti F, Pessia M. Mutations in the KCNA1 gene associated with episodic ataxia type-1 syndrome impair heteromeric voltage-gated K(+) channel function. FASEB J. 1999;13:1335-45.
210. Jan LY, Jan YN. Voltage-gated potassium channels and the diversity of electrical signalling. J Physiol. 2012;590:2591-9.
211. Rea R, Spauschus A, Eunson LH, Hanna MG, Kullmann DM. Variable K(+) channel subunit dysfunction in inherited mutations of KCNA1. J Physiol. 2002;538:5-23. (Pubitemid 35190034)
212. Khavandgar S, Walter JT, Sageser K, Khodakhah K. Kv1 channels selectively prevent dendritic hyperexcitability in rat Purkinje cells. J Physiol. 2005;569:545-57. (Pubitemid 41830121)
213. Herson PS, VirkM, Rustay NR, Bond CT, Crabbe JC, Adelman JP, et al. A mouse model of episodic ataxia type-1. Nat Neurosci. 2003;6:378-83. (Pubitemid 36373983)
214. Ishida S, Sakamoto Y, Nishio T, Baulac S, Kuwamura M, Ohno Y, et al. Kcna1-mutant rats dominantly display myokymia, neuromyotonia and spontaneous epileptic seizures. Brain Res. 2012;1435:154-66.
215. Lee YC, Durr A, Majczenko K, Huang YH, Liu YC, Lien CC, et al. Mutations in KCND3 cause spinocerebellar ataxia type 22. Ann Neurol. 2012;72:859-69.
216. Duarri A, Jezierska J, Fokkens M, Meijer M, Schelhaas HJ, den Dunnen WF, et al. Mutations in potassium channel kcnd3 cause spinocerebellar ataxia type 19. Ann Neurol. 2012;72:870-80.
217. Storey E, Gardner RJ. Spinocerebellar ataxia type 15. Handb Clin Neurol. 2012;103:561-5.
218. Iwaki A, Kawano Y, Miura S, Shibata H, Matsuse D, Li W, et al. Heterozygous deletion of ITPR1, but not SUMF1, in spinocerebellar ataxia type 16. J Med Genet. 2008;45:32-5
219. van de Leemput J, Chandran J, Knight MA, Holtzclaw LA, Scholz S, Cookson MR, et al. Deletion at ITPR1 underlies ataxia in mice and spinocerebellar ataxia 15 in humans. PLoS Genet. 2007;3:e108.
220. Seal RP, Leighton BH, Amara SG. A model for the topology of excitatory amino acid transporters determined by the extracellular accessibility of substituted cysteines. Neuron. 2000;25:695-706.
221. Jen JC, Wan J, Palos TP, Howard BD, Baloh RW. Mutation in the glutamate transporter EAAT1 causes episodic ataxia, hemiplegia, and seizures. Neurology. 2005;65:529-34. (Pubitemid 41170710)
222. Seal RP, Shigeri Y, Eliasof S, Leighton BH, Amara SG. Sulfhydryl modification of V449C in the glutamate transporter EAAT1 abolishes substrate transport but not the substrate-gated anion conductance. Proc Natl Acad Sci U S A. 2001;98:15324-9. (Pubitemid 34014013)
223. Heinzen EL, Swoboda KJ, Hitomi Y, Gurrieri F, Nicole S, de Vries B, et al. De novomutations inATP1A3 cause alternating hemiplegia of childhood. Nat Genet. 2012;44:1030-4
224. de Carvalho AP, Sweadner KJ, Penniston JT, Zaremba J, Liu L, Caton M, et al. Mutations in the Na+/K+-ATPase alpha3 gene ATP1A3 are associated with rapid-onset dystonia parkinsonism. Neuron. 2004;43:169-75.
225. Brashear A, Mink JW, Hill DF, Boggs N, McCall WV, Stacy MA, et al. ATP1A3 mutations in infants: a new rapid-onset dystonia parkinsonism phenotype characterized by motor delay and ataxia. Dev Med Child Neurol. 2012;54:1065-7.
226. Einholm AP, Toustrup-JensenMS, Holm R, Andersen JP, Vilsen B. The rapid-onset dystonia parkinsonism mutation D923N of the Na+, K+-ATPase alpha3 isoform disrupts Na+ interaction at the third Na+site. J Biol Chem. 2010;285:26245-54.
227. Zanni G, Cali T, Kalscheuer VM, Ottolini D, Barresi S, Lebrun N, et al. Mutation of plasma membrane Ca2+ ATPase isoform 3 in a family with X-linked congenital cerebellar ataxia impairs Ca2+homeostasis. Proc Natl Acad Sci U S A. 2012;109:14514-9.
228. Hansen S, Pratap M, Otis T, Pulst SM. Changes in Purkinje cell firing and gene expression precede behavioral pathology in a mouse model of SCA2. Hum Mol Genet. 2013; 22:271-83.
229. Hourez R, Servais L, Orduz D, Gall D, Millard I, de Kerchove d'Exaerde A, et al. Aminopyridines correct early dysfunction and delay neurodegeneration in amouse model of spinocerebellar ataxia type 1. J Neurosci. 2011;31:11795-807.
230. Shakkottai VG, do Carmo Costa M, Dell'Orco JM, Sankaranarayanan A, Wulff H, Paulson HL. Early changes in cerebellar physiology accompany motor dysfunction in the polyglutamine disease spinocerebellar ataxia type 3. J Neurosci. 2011;31:13002-14.
231. Shchelochkov OA, Cheung SW, Lupski JR. Genomic and clinical characteristics of microduplications in chromosome 17. Am J Med Genet. 2010;152A:1101-10.
232. Matsuura T, Yamagata T, Burgess DL, Rasmussen A, Grewal RP, Watase K, et al. Large expansion of the ATTCT pentanucleotide repeat in spinocerebellar ataxia type 10. Nat Genet. 2000;26:191-4.
233. Sato N, Amino T, Kobayashi K, Asakawa S, Ishiguro T, Tsunemi T, et al. Spinocerebellar ataxia type 31 is associated with "inserted"penta- nucleotide repeats containing (TGGAA)n. Am J Hum Genet. 2009;85:544-57.
234. Hagerman RJ, Leehey M, Heinrichs W, Tassone F, Wilson R, Hills J, et al. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology. 2001;57:127-30. (Pubitemid 32634862)
235. Wang JL, Wu YQ, Lei LF, Shen L, Jiang H, Zhou YF, et al. [Polynucleotide repeat expansion of nine spinocerebellar ataxia subtypes and dentatorubral- pallidoluysian atrophy in healthy Chinese Han population]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2010;27:501-5.
236. Wakamiya M, Matsuura T, Liu Y, Schuster GC, Gao R, Xu W, et al. The role of ataxin 10 in the pathogenesis of spinocerebellar ataxia type 10. Neurology. 2006;67:607-13. (Pubitemid 44273606)
237. Keren B, Jacquette A, Depienne C, Leite P, Durr A, Carpentier W, et al. Evidence against haploinsuffiency of human ataxin 10 as a cause of spinocerebellar ataxia type 10. Neurogenetics. 2010;11:273-4.
238. White MC, Gao R, Xu W, Mandal SM, Lim JG, Hazra TK, et al. Inactivation of hnRNP K by expanded intronic AUUCU repeat induces apoptosis via translocation of PKCdelta to mitochondria in spinocerebellar ataxia 10. PLoS Genet. 2010;6:e1000984.
239. White M, Xia G, Gao R, Wakamiya M, Sarkar PS, McFarland K, et al. Transgenic mice with SCA10 pentanucleotide repeats show motor phenotype and susceptibility to seizure: a toxic RNA gain-of-function model. J Neurosci Res. 2012;90:706-14.
240. Chan JY, Huang SM, Liu ST, Huang CH. The transactivation domain of heterogeneous nuclear ribonucleoprotein K overlaps its nuclear shuttling domain. Int J Biochem Cell Biol. 2008;40:2078 -89.
241. Dejgaard K, Leffers H. Characterisation of the nucleic-acid-binding activity of KH domains. Different properties of different domains. Eur J Biochem. 1996;241:425-31. (Pubitemid 26356829)
242. Bomsztyk K, Denisenko O, Ostrowski J. hnRNP K: one protein multiple processes. Bioessays. 2004;26:629-38. (Pubitemid 38758340)
243. Schullery DS, Ostrowski J, Denisenko ON, Stempka L, Shnyreva M, Suzuki H, et al. Regulated interaction of protein kinase Cdelta with the heterogeneous nuclear ribonucleoprotein K protein. J Biol Chem. 1999;274:15101-9.
244. Brodie C, Blumberg PM. Regulation of cell apoptosis by protein kinase c delta. Apoptosis. 2003;8:19-27. (Pubitemid 36133134)
245. Sellier C, Rau F, Liu Y, Tassone F, Hukema RK, Gattoni R, et al. Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients. EMBO J. 2010;29:1248-61.
246. Mankodi A, Urbinati CR, Yuan QP, Moxley RT, Sansone V, Krym M, et al. Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. Hum Mol Genet. 2001;10:2165-70. (Pubitemid 32998828)
247. Jiang H, Mankodi A, Swanson MS, Moxley RT, Thornton CA. Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum Mol Genet. 2004;13:3079-88. (Pubitemid 40045262)
248. Savkur RS, Philips AV, Cooper TA. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet. 2001;29:40-7. (Pubitemid 32801806)
249. Philips AV, Timchenko LT, Cooper TA. Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science. 1998;280:737-41. (Pubitemid 28243348)
250. Charlet BN, Savkur RS, Singh G, Philips AV, Grice EA, Cooper TA. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol Cell. 2002;10:45-53. (Pubitemid 34879148)
251. Mankodi A, Takahashi MP, Jiang H, Beck CL, Bowers WJ, Moxley RT, et al. Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell. 2002;10:35-44. (Pubitemid 34879147)
252. Wheeler TM, Lueck JD, Swanson MS, Dirksen RT, Thornton CA. Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest. 2007;117:3952-7. (Pubitemid 350224104)
253. McFarland KN, Liu J, Landrian I, Gao R, Sarkar PS, Raskin S, et al. Paradoxical effects of repeat interruptions on spinocerebellar ataxia type 10 expansions and repeat instability. Eur J Hum Genet. 2013;21:1272-6.
254. Ranum LP, Chung MY, Banfi S, Bryer A, Schut LJ, Ramesar R, et al. Molecular and clinical correlations in spinocerebellar ataxia type I: evidence for familial effects on the age at onset. Am J Hum Genet. 1994;55:244-52. (Pubitemid 24233207)
255. Quan F, Janas J, Popovich BW. A novel CAG repeat configuration in the SCA1 gene: implications for the molecular diagnostics of spinocerebellar ataxia type 1. Hum Mol Genet. 1995;4:2411-3.
256. Matsuyama Z, Izumi Y, Kameyama M, Kawakami H, Nakamura S. The effect of CAT trinucleotide interruptions on the age at onset of spinocerebellar ataxia type 1 (SCA1). JMed Genet. 1999;36:546-8. (Pubitemid 29301597)
257. Matsuura T, Fang P, Pearson CE, Jayakar P, Ashizawa T, Roa BB, et al. Interruptions in the expanded ATTCT repeat of spinocerebellar ataxia type 10: repeat purity as a disease modifier? Am J Hum Genet. 2006;78:125-9. (Pubitemid 41833165)
258. Spaans F, Faber CG, Smeets HJ, Hofman PA, Braida C, Monckton DG, et al. Encephalopathic attacks in a family co-segregating myotonic dystrophy type 1, an intermediate Charcot-Marie-Tooth neuropathy and early hearing loss. J Neurol Neurosurg Psychiatry. 2009;80:1029-35.
259. Braida C, Stefanatos RK, Adam B, Mahajan N, Smeets HJ, Niel F, et al. Variant CCG and GGC repeats within the CTG expansion dramatically modify mutational dynamics and likely contribute toward unusual symptoms in some myotonic dystrophy type 1 patients. Hum Mol Genet. 2010;19:1399-412.
260. Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069-75.
261. Sakai H, Yoshida K, Shimizu Y, Morita H, Ikeda S, Matsumoto N. Analysis of an insertion mutation in a cohort of 94 patients with spinocerebellar ataxia type 31 from Nagano, Japan. Neurogenetics. 2010;11:409-15.
262. Bonini NM, Gitler AD. Model organisms reveal insight into human neurodegenerative disease: ataxin-2 intermediate-length polyglutamine expansions are a risk factor for ALS. J Mol Neurosci. 2011;45:676-83.
263. Corrado L,Mazzini L, Oggioni GD, Luciano B, GodiM, Brusco A, et al. ATXN-2 CAG repeat expansions are interrupted in ALS patients. Hum Genet. 2011;130:575-80.
264. Ishikawa K, Durr A, Klopstock T, Muller S, De Toffol B, Vidailhet M, et al. Pentanucleotide repeats at the spinocerebellar ataxia type 31 (SCA31) locus in Caucasians. Neurology. 2011;77:1853-5.
265. Yu Z, Zhu Y, Chen-Plotkin AS, Clay-Falcone D, McCluskey L, Elman L, et al. PolyQ repeat expansions in ATXN2 associated with ALS are CAA interrupted repeats. PLoS One. 2011;6:e17951.
266. KoobMD,Moseley ML, Schut LJ, Benzow KA, Bird TD, Day JW, et al. An untranslated CTG expansion causes a novel form of spinocerebellar ataxia (SCA8). Nat Genet. 1999;21:379-84. (Pubitemid 29159573)
267. Cho DH, Thienes CP, Mahoney SE, Analau E, Filippova GN, Tapscott SJ. Antisense transcription and heterochromatin at the DM1 CTG repeats are constrained by CTCF. Mol Cell. 2005;20:483-9. (Pubitemid 41572304)
268. Libby RT, Hagerman KA, Pineda VV, Lau R, Cho DH, Baccam SL, et al. CTCF cis-regulates trinucleotide repeat instability in an epigenetic manner: a novel basis for mutational hot spot determination. PLoS Genet. 2008;4:e1000257.
269. Chung DW, Rudnicki DD, Yu L, Margolis RL. A natural antisense transcript at the Huntington's disease repeat locus regulates HTT expression. Hum Mol Genet. 2011;20:3467-77.
270. Rudnicki DD, Pletnikova O, Vonsattel JP, Ross CA, Margolis RL. A comparison of Huntington disease and Huntington disease-like 2 neuropathology. J Neuropathol Exp Neurol. 2008;67:366-74. (Pubitemid 351507491)
271. Moseley ML, Zu T, Ikeda Y, Gao W, Mosemiller AK, Daughters RS, et al. Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8. Nat Genet. 2006;38:758-69. (Pubitemid 43980596)
272. Ikeda Y, Daughters RS, Ranum LP. Bidirectional expression of the SCA8 expansion mutation: one mutation, two genes. Cerebellum. 2008;7:150-8.
273. Chen IC, Lin HY, Lee GC, Kao SH, Chen CM, Wu YR, et al. Spinocerebellar ataxia type 8 larger triplet expansion alters histone modification and induces RNA foci. BMC Mol Biol. 2009;10:9.
274. Batra R, Charizanis K, Swanson MS. Partners in crime: bidirectional transcription in unstable microsatellite disease. Hum Mol Genet. 2010;19:R77-82.
275. Mykowska A, Sobczak K, Wojciechowska M, Kozlowski P, Krzyzosiak WJ. CAG repeats mimic CUG repeats in the misregulation of alternative splicing. Nucleic Acids Res. 2011;39: 8938-51.
276. Zu T, Gibbens B, Doty NS, Gomes-Pereira M, Huguet A, Stone MD, et al. Non-ATG-initiated translation directed by microsatellite expansions. Proc Natl Acad Sci U S A. 2011;108:260-5.
277. Ash PE, Bieniek KF, Gendron TF, Caulfield T, Lin WL, Dejesus-Hernandez M, et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron. 2013;77:639-46.
278. Pearson CE. Repeat associated non-ATG translation initiation: one DNA, two transcripts, seven reading frames, potentially nine toxic entities! PLoS Genet. 2011;7:e1002018.
279. Finsterer J. Mitochondrial ataxias. Can J Neurol Sci. 2009;36: 543-53.
280. Di Donato S, Marmolino D, Taroni F. Mitochondrial disorders. In: Manto M, Schmahmann J, Rossi F, Gruol D, Koibuchi N, editors. Handbook of the cerebellum and cerebellar disorder. the Netherlands: Springer; 2013. p. 2269-311.
281. Montero R, PinedaM, Aracil A, Vilaseca MA, Briones P, Sanchez- Alcazar JA, et al. Clinical, biochemical and molecular aspects of cerebellar ataxia and coenzyme Q10 deficiency. Cerebellum. 2007;6:118-22. (Pubitemid 46788994)
282. Quinzii CM, Lopez LC, Naini A, DiMauro S, Hirano M. Human CoQ10 deficiencies. Biofactors. 2008;32:113-8.
283. Spindler M, Beal MF, Henchcliffe C. Coenzyme Q10 effects in neurodegenerative disease. Neuropsychiatr Dis Treat. 2009;5:597-610.
284. Lagier-Tourenne C, Tazir M, Lopez LC, Quinzii CM, Assoum M, Drouot N, et al. ADCK3, an ancestral kinase, ismutated in a form of recessive ataxia associated with coenzyme Q10 deficiency. Am J Hum Genet. 2008;82:661-72. (Pubitemid 351735958)
285. Gerards M, van den Bosch B, Calis C, Schoonderwoerd K, van Engelen K, Tijssen M, et al. Nonsense mutations in CABC1/ ADCK3 cause progressive cerebellar ataxia and atrophy. Mitochondrion. 2010;10:510-5.
286. Lu S, Lu LY, Liu MF, Yuan QJ, Sham MH, Guan XY, et al. Cerebellar defects in Pdss2 conditional knockout mice during embryonic development and in adulthood. Neurobiol Dis. 2012;45: 219-33.
287. Spinazzola A, Zeviani M. Disorders of nuclear-mitochondrial intergenomic signaling. Gene. 2005;354:162-8. (Pubitemid 41116697)
288. Copeland WC. Defects in mitochondrial DNA replication and human disease. Crit Rev Biochem Mol Biol. 2012;47:64-74.
289. Kaguni LS. DNA polymerase gamma, the mitochondrial replicase. Annu Rev Biochem. 2004;73:293-320. (Pubitemid 39050371)
290. Wong LJ, Naviaux RK, Brunetti-Pierri N, Zhang Q, Schmitt ES, Truong C, et al. Molecular and clinical genetics of mitochondrial diseases due to POLG mutations. Hum Mutat. 2008;29:E150-72.
291. Hakonen AH, Heiskanen S, Juvonen V, Lappalainen I, Luoma PT, Rantamaki M, et al. Mitochondrial DNA polymerase W748S mutation: a common cause of autosomal recessive ataxia with ancient European origin. Am J Hum Genet. 2005;77:430-41. (Pubitemid 41192649)
292. Milone M, Brunetti-Pierri N, Tang LY, Kumar N, Mezei MM, Josephs K, et al. Sensory ataxic neuropathy with ophthalmoparesis caused by POLG mutations. Neuromuscul Disord. 2008;18:626-32.
293. Nikali K, Suomalainen A, Saharinen J, Kuokkanen M, Spelbrink JN, Lonnqvist T, et al. Infantile onset spinocerebellar ataxia is caused by recessive mutations in mitochondrial proteins Twinkle and Twinky. Hum Mol Genet. 2005;14:2981-90. (Pubitemid 41535463)
294. Sykora P, Croteau DL, Bohr VA, Wilson 3rd DM. Aprataxin localizes to mitochondria and preserves mitochondrial function. Proc Natl Acad Sci U S A. 2011;108:7437-42.
295. Das BB, Dexheimer TS, Maddali K, Pommier Y. Role of tyrosyl- DNA phosphodiesterase (TDP1) in mitochondria. Proc Natl Acad Sci U S A. 2010;107:19790-5.
296. Pandolfo M, Pastore A. The pathogenesis of Friedreich ataxia and the structure and function of frataxin. J Neurol. 2009;256 Suppl 1:9-17.
297. Marmolino D. Friedreich's ataxia: past, present and future. Brain Res Rev. 2011;67:311-30.
298. Martelli A, Napierala M, Puccio H. Understanding the genetic and molecular pathogenesis of Friedreich's ataxia through animal and cellular models. Dis Model Mech. 2012;5:165-76.
299. Martelli A, Wattenhofer-Donze M, Schmucker S, Bouvet S, Reutenauer L, Puccio H. Frataxin is essential for extramitochondrial Fe -S cluster proteins in mammalian tissues. Hum Mol Genet. 2007;16:2651-8. (Pubitemid 350018507)
300. Babcock M, de Silva D, Oaks R, Davis-Kaplan S, Jiralerspong S, Montermini L, et al. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science. 1997;276: 1709- 12.
301. Puccio H, Simon D, Cossee M, Criqui-Filipe P, Tiziano F, Melki J, et al. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet. 2001;27:181-6. (Pubitemid 32157445)
302. Wong A,Yang J, Cavadini P, Gellera C, Lonnerdal B, Taroni F, et al. The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum Mol Genet. 1999;8:425-30. (Pubitemid 29097330)
303. DiMauro S, Schon EA. Mitochondrial disorders in the nervous system. Annu Rev Neurosci. 2008;31:91-123.
304. Schon EA, Przedborski S. Mitochondria: the next (neurode)generation. Neuron. 2011;70:1033-53.
305. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev. 2007;87:99-163. (Pubitemid 46209992)
306. Choo YS, Johnson GV, MacDonald M, Detloff PJ, Lesort M. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum Mol Genet. 2004;13:1407-20. (Pubitemid 39023049)
307. Lipinski MM, Yuan J. Mechanisms of cell death in polyglutamine expansion diseases. Curr Opin Pharmacol. 2004;4:85-90. (Pubitemid 38145843)
308. Chou AH, Yeh TH, Kuo YL, Kao YC, Jou MJ, Hsu CY, et al. Polyglutamine-expanded ataxin-3 activates mitochondrial apoptotic pathway by upregulating Bax and downregulating Bcl-xL. Neurobiol Dis. 2006;21:333-45.
309. Wang HL, Yeh TH, Chou AH, Kuo YL, Luo LJ, He CY, et al. Polyglutamine-expanded ataxin-7 activates mitochondrial apoptotic pathway of cerebellar neurons by upregulating Bax and downregulating Bcl-x(L). Cell Signal. 2006;18:541-52.
310. Laco MN, Oliveira CR, Paulson HL, Rego AC. Compromised mitochondrial complex II in models of Machado-Joseph disease. Biochim Biophys Acta. 1822;2012:139-49.
311. Ruan Q, Lesort M,MacDonaldME, Johnson GV. Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a nonapoptotic pathway. Hum Mol Genet. 2004;13:669-81. (Pubitemid 38455955)
312. Youle RJ, Karbowski M. Mitochondrial fission in apoptosis. Nat Rev Mol Cell Biol. 2005;6:657-63. (Pubitemid 41081269)
313. Chan DC. Mitochondria: dynamic organelles in disease, aging, and development. Cell. 2006;125:1241-52. (Pubitemid 43929096)
314. Liesa M, Palacin M, Zorzano A. Mitochondrial dynamics in mammalian health and disease. Physiol Rev. 2009;89:799-845.
315. Chan DC. Mitochondrial dynamics in disease. N Engl J Med. 2007;356:1707-9. (Pubitemid 46658702)
316. Chen H, McCaffery JM, Chan DC.Mitochondrial fusion protects against neurodegeneration in the cerebellum. Cell. 2007;130: 548-62. (Pubitemid 47198302)
317. Dagda RK, Merrill RA, Cribbs JT, Chen Y, Hell JW, Usachev YM, et al. The spinocerebellar ataxia 12 gene product and protein phosphatase 2A regulatory subunit Bbeta2 antagonizes neuronal survival by promoting mitochondrial fission. J Biol Chem. 2008;283:36241-8.
318. Lin CH, Chen CM, Hou YT, Wu YR, Hsieh-Li HM, Su MT, et al. The CAG repeat in SCA12 functions as a cis element to up-regulate PPP2R2B expression. Hum Genet. 2010;128:205-12.
319. Girard M, Lariviere R, Parfitt DA, Deane EC, Gaudet R, Nossova N, et al. Mitochondrial dysfunction and Purkinje cell loss in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS). Proc Natl Acad Sci U S A. 2012;109:1661-6.
320. WangYC, LeeCM, Lee LC, Tung LC,Hsieh-LiHM, Lee-Chen GJ, et al. Mitochondrial dysfunction and oxidative stress contribute to the pathogenesis of spinocerebellar ataxia type 12 (SCA12). J Biol Chem. 2011;286:21742-54.
321. Rugarli EI, Langer T. Mitochondrial quality control: a matter of life and death for neurons. EMBO J. 2012;31:1336-49.
322. Di Bella D, Lazzaro F, Brusco A, Plumari M, Battaglia G, Pastore A, et al. Mutations in the mitochondrial protease gene AFG3L2 cause dominant hereditary ataxia SCA28. Nat Genet. 2010;42:313-21.
323. Casari G, De Fusco M, Ciarmatori S, Zeviani M, Mora M, Fernandez P, et al. Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease. Cell. 1998;93:973-83. (Pubitemid 28280791)
324. Tatsuta T, Langer T. Quality control of mitochondria: protection against neurodegeneration and ageing. EMBO J. 2008;27:306-14. (Pubitemid 351161660)
325. Cagnoli C, Stevanin G, Brussino A, Barberis M, Mancini C, Margolis RL, et al. Missense mutations in the AFG3L2 proteolytic domain account for approximately 1.5% of European autosomal dominant cerebellar ataxias. Hum Mutat. 2010;31:1117-24.
326. Pierson TM, Adams D, Bonn F,Martinelli P, Cherukuri PF, Teer JK, et al. Whole-exome sequencing identifies homozygous AFG3L2 mutations in a spastic ataxia-neuropathy syndrome linked to mitochondrial m-AAA proteases. PLoS Genet. 2011;7:e1002325.
327. Mariotti C, Brusco A, Di Bella D, Cagnoli C, Seri M, Gellera C, et al. Spinocerebellar ataxia type 28: a novel autosomal dominant cerebellar ataxia characterized by slow progression and ophthalmoparesis. Cerebellum. 2008;7:184-8.
328. Almajan ER, Richter R, Paeger L, Martinelli P, Barth E, Decker T, et al. AFG3L2 supports mitochondrial protein synthesis and Purkinje cell survival. J Clin Invest. 2012;122:4048-58.
329. Maltecca F, De Stefani D, Cassina L, Consolato F, Wasilewski M, Scorrano L, et al. Respiratory dysfunction by AFG3L2 deficiency causes decreased mitochondrial calcium uptake via organellar network fragmentation. Hum Mol Genet. 2012;21:3858-70.
330. Perlman SL. A review of Friedreich ataxia clinical trial results. J Child Neurol. 2012;27:1217-22.
331. Ilg W, Synofzik M, Brotz D, Burkard S, Giese MA, Schols L. Intensive coordinative training improves motor performance in degenerative cerebellar disease. Neurology. 2009;73:1823-30.
332. IlgW, Brotz D, Burkard S, GieseMA, Schols L, SynofzikM. Longterm effects of coordinative training in degenerative cerebellar disease. Mov Disord. 2010;25:2239-46.
333. Soragni E, Herman D, Dent SY, Gottesfeld JM, Wells RD, Napierala M. Long intronic GAA&z.ast;TTC repeats induce epigenetic changes and reporter gene silencing in a molecular model of Friedreich ataxia. Nucleic Acids Res. 2008;36:6056-65.
334. Rai M, Soragni E, Jenssen K, Burnett R, Herman D, Coppola G, et al. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS One. 2008;3:e1958.
335. Rai M, Soragni E, Chou CJ, Barnes G, Jones S, Rusche JR, et al. Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells fromFriedreich's ataxia patients and in a mouse model. PLoS One. 2010;5:e8825.
336. Herman D, Jenssen K, Burnett R, Soragni E, Perlman SL, Gottesfeld JM. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol. 2006;2:551-8. (Pubitemid 44413238)
337. Xu C, Soragni E, Chou CJ, Herman D, Plasterer HL, Rusche JR, et al. Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencing. Chem Biol. 2009;16:980-9.
338. Shan G, Xu S, Jin P. FXTAS: a bad RNA and a hope for a cure. Expert Opin Biol Ther. 2008;8:249-53. (Pubitemid 351428414)
339. Todd PK, Oh SY, Krans A, Pandey UB, Di Prospero NA, Min KT, et al. Histone deacetylases suppress CGG repeat-induced neurodegeneration via transcriptional silencing inmodels of fragile X tremor ataxia syndrome. PLoS Genet. 2010;6:e1001240.
340. Xia H, Mao Q, Eliason SL, Harper SQ, Martins IH, Orr HT, et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med. 2004;10:816-20. (Pubitemid 39070854)
341. Scholefield J, Greenberg LJ, Weinberg MS, Arbuthnot PB, Abdelgany A, Wood MJ. Design of RNAi hairpins for mutation-specific silencing of ataxin-7 and correction of a SCA7 phenotype. PLoS One. 2009;4:e7232.
342. Hu J, Gagnon KT, Liu J, Watts JK, Syeda-Nawaz J, Bennett CF, et al. Allele-selective inhibition of ataxin-3 (ATX3) expression by antisense oligomers and duplex RNAs. Biol Chem. 2011;392: 315-25.
343. Fiszer A, Olejniczak M, Switonski PM, Wroblewska JP, Wisniewska-Kruk J, Mykowska A, et al. An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases. BMC Mol Biol. 2012;13:6.
344. Tsou WL, Soong BW, Paulson HL, Rodriguez-Lebron E. Splice isoform-specific suppression of the Cav2.1 variant underlying spinocerebellar ataxia type 6. Neurobiol Dis. 2011;43:533-42.
345. Bowers WJ, Breakefield XO, Sena-Esteves M. Genetic therapy for the nervous system. Hum Mol Genet. 2011;20:R28-41.
346. Pandolfo M. Drug insight: antioxidant therapy in inherited ataxias. Nat Clin Pract Neurol. 2008;4:86-96. (Pubitemid 351248066)
347. Lynch DR, Willi SM, Wilson RB, Cotticelli MG, Brigatti KW, Deutsch EC, et al. A0001 in Friedreich ataxia: biochemical characterization and effects in a clinical trial. Mov Disord. 2012;27: 1026-33.
348. Broccoletti T, Del Giudice E, Amorosi S, Russo I, Di Bonito M, Imperati F, et al. Steroid-induced improvement of neurological signs in ataxia-telangiectasia patients. Eur J Neurol. 2008;15:223-8. (Pubitemid 351257930)
349. Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10:83-98.
350. Gottesfeld JM, Pandolfo M. Development of histone deacetylase inhibitors as therapeutics for neurological disease. Future Neurol. 2009;4:775-84.
351. Chou AH, Chen SY, Yeh TH, Weng YH, Wang HL. HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3. Neurobiol Dis. 2011;41:481-8.
352. Schorge S, van de Leemput J, Singleton A, Houlden H, Hardy J. Human ataxias: a genetic dissection of inositol triphosphate receptor (ITPR1)-dependent signaling. Trends Neurosci. 2010;33:211-9.
353. Kasumu AW, Liang X, Egorova P, Vorontsova D, Bezprozvanny I. Chronic suppression of inositol 1,4,5-triphosphate receptor-mediated calcium signaling in cerebellar Purkinje cells alleviates pathological phenotype in spinocerebellar ataxia 2 mice. J Neurosci. 2012;32:12786-96.
354. Stevanin G, Durr A, Brice A. Clinical and molecular advances in autosomal dominant cerebellar ataxias: from genotype to phenotype and physiopathology. Eur J Hum Genet. 2000;8:4-18. (Pubitemid 30113790)
355. Netravathi M, Pal PK, Purushottam M, Thennarasu K, Mukherjee M, Jain S. Spinocerebellar ataxias types 1, 2 and 3: age adjusted clinical severity of disease at presentation correlates with size of CAG repeat lengths. J Neurol Sci. 2009;277:83-6.
356. Ikeuchi T, Koide R, Tanaka H, Onodera O, Igarashi S, Takahashi H, et al. Dentatorubral-pallidoluysian atrophy: clinical features are closely related to unstable expansions of trinucleotide (CAG) repeat. Ann Neurol. 1995;37:769-75.
357. Komure O, Sano A, Nishino N, Yamauchi N, Ueno S, Kondoh K, et al. DNA analysis in hereditary dentatorubral-pallidoluysian atrophy: correlation between CAG repeat length and phenotypic variation and the molecular basis of anticipation. Neurology. 1995;45:143-9.
358. Charles P, Camuzat A, Benammar N, Sellal F, Destee A, Bonnet AM, et al. Are interrupted SCA2 CAG repeat expansions responsible for parkinsonism? Neurology. 2007;69:1970-5. (Pubitemid 350145088)
359. Modoni A, Contarino MF, Bentivoglio AR, Tabolacci E, Santoro M, Calcagni ML, et al. Prevalence of spinocerebellar ataxia type 2 mutation among Italian parkinsonian patients. Mov Disord. 2007;22:324-7. (Pubitemid 46569684)
360. Maciel P, Gaspar C, DeStefano AL, Silveira I, Coutinho P, Radvany J, et al. Correlation between CAG repeat length and clinical features in Machado-Joseph disease. Am J Hum Genet. 1995;57:54-61.
361. Durr A, Stevanin G, Cancel G, Duyckaerts C, Abbas N, Didierjean O, et al. Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features. Ann Neurol. 1996;39:490-9. (Pubitemid 26118004)
362. David G, Durr A, Stevanin G, Cancel G, Abbas N, Benomar A, et al. Molecular and clinical correlations in autosomal dominant cerebellar ataxia with progressive macular dystrophy (SCA7). Hum Mol Genet. 1998;7:165-70. (Pubitemid 28048530)
363. DeStefano AL, Cupples LA, Maciel P, Gaspar C, Radvany J, Dawson DM, et al. A familial factor independent of CAG repeat length influences age at onset of Machado-Joseph disease. Am J Hum Genet. 1996;59:119-27
364. van de Warrenburg BP, Hendriks H, Durr A, van Zuijlen MC, Stevanin G, Camuzat A, et al. Age at onset variance analysis in spinocerebellar ataxias: a study in a Dutch-French cohort. Ann Neurol. 2005;57:505-12.
365. Hayes S, Turecki G, Brisebois K, Lopes-Cendes I, Gaspar C, Riess O, et al. CAG repeat length in RAI1 is associated with age at onset variability in spinocerebellar ataxia type 2 (SCA2). Hum Mol Genet. 2000;9:1753-8. (Pubitemid 30608609)
366. Chattopadhyay B, Ghosh S, Gangopadhyay PK, Das SK, Roy T, Sinha KK, et al. Modulation of age at onset in Huntington's disease and spinocerebellar ataxia type 2 patients originated from eastern India. Neurosci Lett. 2003;345:93-6. (Pubitemid 36734870)
367. Jardim L, Silveira I, Pereira ML, do Ceu Moreira M, Mendonca P, Sequeiros J, et al. Searching for modulating effects of SCA2, SCA6 and DRPLA CAG tracts on the Machado-Joseph disease (SCA3) phenotype. Acta Neurol Scand. 2003;107:211-4. (Pubitemid 36398997)
368. Latouche M, Lasbleiz C, Martin E, Monnier V, Debeir T, Mouatt- Prigent A, et al. A conditional pan-neuronal Drosophila model of spinocerebellar ataxia 7 with a reversible adult phenotype suitable for identifying modifier genes. J Neurosci. 2007;27:2483-92. (Pubitemid 46393606)
369. Lessing D, Bonini NM. Polyglutamine genes interact to modulate the severity and progression of neurodegeneration in Drosophila. PLoS Biol. 2008;6:e29.
370. Vo SH, Butzlaff M, Pru SK, Ni Charthaigh RA, Karsten P, Lankes A, et al. Large-scale screen for modifiers of ataxin-3-derived polyglutamine-induced toxicity in Drosophila . PLoS One. 2012;7: e47452.
371. Fujigasaki H, Martin JJ, De Deyn PP, Camuzat A, Deffond D, Stevanin G, et al. CAG repeat expansion in the TATA box-binding protein gene causes autosomal dominant cerebellar ataxia. Brain. 2001;124:1939-47. (Pubitemid 32945895)
372. Bruni AC, Takahashi-Fujigasaki J, Maltecca F, Foncin JF, Servadio A, Casari G, et al. Behavioral disorder, dementia, ataxia, and rigidity in a large family with TATA box-binding protein mutation. Arch Neurol. 2004;61:1314-20. (Pubitemid 39062691)
373. Rolfs A, Koeppen AH, Bauer I, Bauer P, Buhlmann S, Topka H, et al. Clinical features and neuropathology of autosomal dominant spinocerebellar ataxia (SCA17). Ann Neurol. 2003;54:367-75. (Pubitemid 37072039)
374. Emamian ES, Kaytor MD, Duvick LA, Zu T, Tousey SK, Zoghbi HY, et al. Serine 776 of ataxin-1 is critical for poly glutamine-induced disease in SCA1 transgenic mice. Neuron. 2003;38: 375-87. (Pubitemid 36579141)
375. Kaytor MD, Byam CE, Tousey SK, Stevens SD, Zoghbi HY, Orr HT. A cell-based screen formodulators of ataxin-1 phosphorylation. Hum Mol Genet. 2005;14:1095-105. (Pubitemid 40575885)
376. Janer A, Werner A, Takahashi-Fujigasaki J, Daret A, Fujigasaki H, Takada K, et al. SUMOylation attenuates the aggregation propensity and cellular toxicity of the polyglutamine expanded ataxin-7. Hum Mol Genet. 2010;19:181-95.
377. Warrick JM, Chan HY, Gray-Board GL, Chai Y, Paulson HL, Bonini NM. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat Genet. 1999;23:425-8.
378. Chan HY, Warrick JM, Gray-Board GL, Paulson HL, Bonini NM. Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy and modulation of protein solubility in Drosophila . Hum Mol Genet. 2000;9:2811-20.
379. Kazemi-Esfarjani P, Benzer S. Genetic suppression of polyglutamine toxicity in Drosophila. Science. 2000;287:1837 - 40.
380. Cummings CJ, Sun Y, Opal P, Antalffy B, Mestril R, Orr HT, et al. Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. Hum Mol Genet. 2001;10:1511-8. (Pubitemid 32684893)
381. Kimura Y, Koitabashi S, Kakizuka A, Fujita T. Initial process of polyglutamine aggregate formation in vivo. Genes Cells. 2001;6: 887-97. (Pubitemid 33019742)
382. Higashiyama H, Hirose F, Yamaguchi M, Inoue YH, Fujikake N, Matsukage A, et al. Identification of ter94, Drosophila VCP, as a modulator of polyglutamine-induced neurodegeneration. Cell Death Differ. 2002;9:264-73.
383. van Dellen A, Blakemore C, Deacon R, York D, Hannan AJ. Delaying the onset ofHuntington's inmice. Nature. 2000;404:721-2.
384. Imbert G, Saudou F, Yvert G, Devys D, Trottier Y, Garnier JM, et al. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet. 1996;14:285-91.
385. Pulst SM, Nechiporuk A, Nechiporuk T, Gispert S, Chen XN, Lopes-Cendes I, et al. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet. 1996;14:269-76.
386. Sanpei K, Takano H, Igarashi S, Sato T, Oyake M, Sasaki H, et al. Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nat Genet. 1996;14:277-84.
387. Kawaguchi Y, Okamoto T, Taniwaki M, Aizawa M, Inoue M, Katayama S, et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet. 1994;8:221-7.
388. Hellenbroich Y, Pawlack H, Rub U, Schwinger E, Zuhlke C. Spinocerebellar ataxia type 4. Investigation of 34 candidate genes. J Neurol. 2005;252:1472-5. (Pubitemid 41803836)
389. Ikeda Y, Dick KA, Weatherspoon MR, Gincel D, Armbrust KR, Dalton JC, et al. Spectrin mutations cause spinocerebellar ataxia type 5. Nat Genet. 2006;38:184-90. (Pubitemid 43177231)
390. David G, Abbas N, Stevanin G, Durr A, Yvert G, Cancel G, et al. Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat Genet. 1997;17:65-70. (Pubitemid 27377533)
391. Higgins JJ, Pho LT, Ide SE, Nee LE, Polymeropoulos MH. Evidence for a new spinocerebellar ataxia locus. Mov Disord. 1997;12:412-7. (Pubitemid 27216142)
392. O'Hearn E, Holmes SE, Margolis RL. Spinocerebellar ataxia type 12. Handb Clin Neurol. 2012;103:535-47.
393. Stevanin G, Durr A. Spinocerebellar ataxia 13 and 25. Handb Clin Neurol. 2012;103:549-53.
394. Chen DH, Brkanac Z, Verlinde CL, Tan XJ, Bylenok L, Nochlin D, et al. Missense mutations in the regulatory domain of PKCgamma: a new mechanism for dominant nonepisodic cerebellar ataxia. Am J Hum Genet. 2003;72:839-49. (Pubitemid 36403304)
395. Brkanac Z, Fernandez M, Matsushita M, Lipe H, Wolff J, Bird TD, et al. Autosomal dominant sensory/motor neuropathy with ataxia (SMNA): linkage to chromosome 7q22-q32. Am J Med Genet. 2002;114:450-7. (Pubitemid 34525245)
396. Brkanac Z, Spencer D, Shendure J, Robertson PD, Matsushita M, Vu T, et al. IFRD1 is a candidate gene for SMNA on chromosome 7q22-q23. Am J Hum Genet. 2009;84:692-7.
397. KnightMA, Hernandez D, Diede SJ, Dauwerse HG, Rafferty I, van de Leemput J, et al. A duplication at chromosome 11q12.2-11q12.3 is associated with spinocerebellar ataxia type 20. Hum Mol Genet. 2008;17:3847-53.
398. Vuillaume I, Devos D, Schraen-Maschke S, Dina C, Lemainque A, Vasseur F, et al. A new locus for spinocerebellar ataxia (SCA21) maps to chromosome 7p21.3-p15.1. Ann Neurol. 2002;52:666-70. (Pubitemid 35246875)
399. Delplanque J, Devos D, Vuillaume I, De Becdelievre A, Vangelder E, Maurage CA, et al. Slowly progressive spinocerebellar ataxia with extrapyramidal signs and mild cognitive impairment (SCA21). Cerebellum. 2008;7:179-83.
400. Verbeek DS, van de Warrenburg BP, Wesseling P, Pearson PL, Kremer HP, Sinke RJ. Mapping of the SCA23 locus involved in autosomal dominant cerebellar ataxia to chromosome region 20p13-12.3. Brain. 2004;127:2551-7. (Pubitemid 39472983)
401. Hekman KE, Yu GY, Brown CD, Zhu H, Du X, Gervin K, et al. A conserved eEF2 coding variant in SCA26 leads to loss of translational fidelity and increased susceptibility to proteostatic insult. Hum Mol Genet. 2012;21:5472-83.
402. Brusse E, de Koning I, Maat-Kievit A, Oostra BA, Heutink P, van Swieten JC. Spinocerebellar ataxia associated with a mutation in the fibroblast growth factor 14 gene (SCA27): a new phenotype. Mov Disord. 2006;21:396-401.
403. Mariotti C, Bella DD, Di Donato S, Taroni F. Spinocerebellar ataxia type 28. Handb Clin Neurol. 2012;103:575-9.
404. Dudding TE, Friend K, Schofield PW, Lee S, Wilkinson IA, Richards RI. Autosomal dominant congenital non-progressive ataxia overlaps with the SCA15 locus. Neurology. 2004;63:2288-92. (Pubitemid 40024338)
405. Storey E, Bahlo M, Fahey M, Sisson O, Lueck CJ, Gardner RJ. A new dominantly inherited pure cerebellar ataxia, SCA 30. J Neurol Neurosurg Psychiatry. 2009;80:408-11.
406. Jiang H, Zhu H-P, Gomez CM. SCA32: an autosomal dominant cerebellar ataxia with azoospermia maps to chromosome 7q32-q33. Abstract. Mov Disord. 2010;S192.
407. Giroux JM, Barbeau A. Erythrokeratodermia with ataxia. Arch Dermatol. 1972;106:183-8.
408. Wang JL, Yang X, Xia K, Hu ZM, Weng L, Jin X, et al. TGM6 identified as a novel causative gene of spinocerebellar ataxias using exome sequencing. Brain. 2010;133:3510-8.
409. LiM, Pang SY, Song Y, Kung MH, Ho SL, Sham PC. Whole exome sequencing identifies a novel mutation in the transglutaminase 6 gene for spinocerebellar ataxia in a Chinese family. Clin Genet. 2013;83:269-73.
410. Serrano-Munuera C, Corral-Juan M, Stevanin G, San Nicolas H, Roig C, Corral J, et al. New subtype of spinocerebellar ataxia with altered vertical eye movements mapping to chromosome 1p32. JAMA Neurol. 2013;70:764-71.
411. Koide R, Ikeuchi T, Onodera O, Tanaka H, Igarashi S, Endo K, et al. Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). Nat Genet. 1994;6:9-13.
412. Nagafuchi S,YanagisawaH, Sato K, Shirayama T, Ohsaki E, Bundo M, et al. Dentatorubral and pallidoluysian atrophy expansion of an unstable CAG trinucleotide on chromosome 12p. Nat Genet. 1994;6:14-8.
413. Yabe I, Sasaki H, Kikuchi S, Nonaka M, Moriwaka F, Tashiro K. Late onset ataxia phenotype in dentatorubro-pallidoluysian atrophy (DRPLA). J Neurol. 2002;249:432-6. (Pubitemid 34304617)
414. Amino T, Ishikawa K, Toru S, Ishiguro T, Sato N, Tsunemi T, et al. Redefining the disease locus of 16q22.1-linked autosomal dominant cerebellar ataxia. J Hum Genet. 2007;52:643-9. (Pubitemid 47106486)
415. Onodera Y, Aoki M, Mizuno H, Warita H, Shiga Y, Itoyama Y. Clinical features of chromosome 16q22.1 linked autosomal dominant cerebellar ataxia in Japanese. Neurology. 2006;67:1300-2. (Pubitemid 44563851)
416. Swartz BE, Burmeister M, Somers JT, Rottach KG, Bespalova IN, Leigh RJ. A form of inherited cerebellar ataxia with saccadic intrusions, increased saccadic speed, sensory neuropathy, and myoclonus. Ann N YAcad Sci. 2002;956:441-4. (Pubitemid 34457638)